Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04995042

A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Hormone Sensitive Prostate Cancer Clinical Trial

Official title:
An Open-Label, Multicenter, Dose Escalation And Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer

Clinical Trial Summary

This is an open-label, multicenter, dose escalation and expansion Phase 1 study of SHR7280 in adult patients with hormone sensitive prostate cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04995042
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact
Status Completed
Phase Phase 1
Start date September 24, 2021
Completion date May 25, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06193993 - Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients Phase 1
Active, not recruiting NCT04126070 - Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors Phase 2
Not yet recruiting NCT04182594 - Cardiovascular Events in GnRH Agonist vs. Antagonist Phase 2
Not yet recruiting NCT04220398 - Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer N/A
Active, not recruiting NCT02319837 - Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) Phase 3
Not yet recruiting NCT06463457 - Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) Phase 2
Recruiting NCT06392295 - PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer Phase 2
Recruiting NCT05983783 - Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC Phase 3
Recruiting NCT05352178 - Metastasis-directed Therapy for Oligorecurrent Prostate Cancer Phase 3